AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 121 min read$NTRA

Rabinowitz Matthew sold $16.4M of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 50,000 shares of Natera, Inc. (NTRA) at an average of $327.97 ($325.01–$329.62, $16.40M total) across 6 trades on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Sep 12, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, making it a primary source of new information.

02

Market read

Insider sell of this size may prompt short‑term price pressure, but the pre‑arranged nature tempers the signal.

03

What to watch

The 10b5‑1 plan indicates pre‑planned execution, reducing the informational weight of the sale.

Relevance 6/10Novelty 7/10Timing: after-market 2026-09-11

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑scheduled sales.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

Executive Chairman Matthew Rabinowitz sold 50,000 shares for $16.4M via a 10b5‑1 plan, reducing his stake to 2,225,394 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

A $16M sale by a top executive is material and disclosed first via Form 4; markets often react negatively to sizable insider disposals.

Market effects

Sector

Minimal; biotech sector may see slight sentiment drag from insider sell.

Regional

U.S. market only; no broader regional effect.

Global

Low; limited to Natera investors.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.

Key entities

  • Executive
    Matthew Rabinowitz

    Executive Chairman of Natera, Inc.

  • Company
    Natera, Inc.

    Genomics testing company listed on NASDAQ.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

SEP 9
$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

yahoo.com2 min
SEP 2
$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

etfdb.com3 min
AUG 24
$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

fool.com2 min